Drugs / Retatrutide
Retatrutide
also known as
LY3437943
Protein / enzyme biologic targets GCGR, GIPR, GLP1R via activation
Trials 34
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 115 trials | ||||||
| Phase 1 | NCT06982846 | Jun 2025 → May 2026 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06982859 | Jun 2025 → Jan 2027 expected | type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06808802 | Feb → Apr 2025 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06313528 | Mar 2024 → Aug 2025 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06039826 | Sep 2023 → Jul 2024 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT06003465 | Aug 2023 → Feb 2024 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05959096 | Jul 2023 → Jul 2024 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05916560 | Jul 2023 → Mar 2025 | liver disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05757531 | Mar → Jun 2023 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05611957 | Nov 2022 → Sep 2023 | impaired renal function disease | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05548231 | Oct 2022 → Jul 2023 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05445232 | Jul 2022 → Feb 2023 | obesity disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04823208 | May 2021 → Jun 2022 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04143802 | Dec 2019 → Dec 2020 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03841630 | Mar → Jul 2019 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 24 trials · 2 met primary | ||||||
| Phase 2 | NCT07467447 | Feb 2026 → Mar 2027 expected | obesity disorder | Hudson Biotech | Recruiting | No outcome recorded |
| Phase 2 | NCT05936151 | Jul 2023 → Oct 2025 | chronic kidney disease, obesity disorder, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT04881760 | May 2021 → May 2022 | obesity disorder | Eli Lilly and Company | Completed | Met primary |
| Phase 2 | NCT04867785 | May 2021 → Jul 2022 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 314 trials · 4 met primary | ||||||
| Phase 3 | NCT07357415 | Jan 2026 → Oct 2028 expected | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07232719 | Nov 2025 → Jul 2027 expected | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07165028 | Oct 2025 → Aug 2030 expected | metabolic dysfunction-associated steatotic liver disease | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT07035093 | May 2025 → Sep 2027 expected | chronic pain syndrome, obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06859268 | Mar 2025 → Apr 2028 expected | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06662383 | Nov 2024 → Nov 2026 expected | obesity disorder | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06383390 | Apr 2024 → Feb 2029 expected | atherosclerotic cardiovascular disease, chronic kidney disease | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06354660 | Apr 2024 → Jan 2026 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT06297603 | Mar 2024 → Oct 2026 expected | type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06260722 | Feb 2024 → Aug 2026 overdue | type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05931367 | Aug 2023 → Nov 2025 | obesity disorder, osteoarthritis, knee | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT05929079 | Jul 2023 → May 2026 overdue | obesity disorder, obstructive sleep apnea syndrome, type 2 diabetes mellitus | Eli Lilly and Company | Active not recruiting | Met primary |
| Phase 3 | NCT05929066 | Jul 2023 → Apr 2026 | obesity disorder, obstructive sleep apnea syndrome, osteoarthritis, knee | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT05882045 | May 2023 → Apr 2026 overdue | cardiovascular disorder, obesity disorder | Eli Lilly and Company | Active not recruiting | Met primary |
| Phase not stated1 trial | ||||||
| — | NCT07629401 | — | — | Eli Lilly and Company | Available | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2026-09-29 | Eli Lilly and Company | Results Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes lilly.com ↗
At 80 weeks, all doses of retatrutide (4 mg, 9 mg, and 12 mg) delivered substantial weight loss and reductions in A1C. |
| 2026-09-15 | Eli Lilly and Company | Results Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health lilly.com ↗
TRIUMPH-2: Adults with obesity or overweight and type 2 diabetes taking retatrutide lost up to an average of 49.6 lbs (22.5 kg; 20.8%) and lowered their A1C by up to an average of 1.6% at 80 weeks. |
| 2026-07-23 | Eli Lilly and Company | Results Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C lilly.com ↗
In both studies, retatrutide met the primary endpoint, delivering substantial weight loss in adults with obesity and some of its most serious complications: type 2 diabetes and established cardiovascular disease. |
| 2026-06-06 | Eli Lilly and Company | Results Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications lilly.com ↗
In TRANSCEND-T2D-1, participants on retatrutide achieved A1C reductions of up to 2.0% and weight loss of up to 36.6 lbs (16.8%) at 40 weeks, with up to 46% achieving a normal A1C |
| 2026-05-28 | Eli Lilly and Company | Results Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care lilly.com ↗
Retatrutide delivered powerful weight loss of up to an average of 70.3 lbs (28.3%) at 80 weeks in adults with obesity. |
| 2026-05-21 | Eli Lilly and Company | Results Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial lilly.com ↗
At 80 weeks, all doses of retatrutide (4 mg, 9 mg, and 12 mg) met the primary and key secondary endpoints for obesity, delivering clinically meaningful weight loss. |
| 2026-03-19 | Eli Lilly and Company | Results Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes lilly.com ↗
In the study, retatrutide met the primary and all key secondary endpoints, delivering superior A1C reduction and weight loss at 40 weeks compared to placebo, using both the efficacy and treatment-regimen estimands. |
| 2025-12-11 | Eli Lilly and Company | Results Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial lilly.com ↗
In TRIUMPH-4, participants with obesity and knee osteoarthritis taking retatrutide 12 mg lost an average of 28.7% of their body weight at 68 weeks |
| 2023-06-26 | Eli Lilly and Company | Results Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight lilly.com ↗
In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% (57.8 lb. or 26.2 kg)ii at the end of the 48-week treatment duration. |
All press releases naming this drug 10 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Retatrutide | “Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors.” PMID 37366315 ↗ Jun 2023 |
| Known as | LY3437943 | “A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease” NCT05882045 ↗ |
| Action | Activate | “agonist activity for glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) receptors” PMID 36354040 ↗ Oct 20223“Gastric inhibitory polypeptide receptor agonist” CHEMBL5095485 ↗ “Glucagon-like peptide 1 receptor agonist” CHEMBL5095485 ↗ “Glucagon receptor agonist” CHEMBL5095485 ↗ |
| Modality | Peptide | “LY3437943 is a single peptide with agonist activity for glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) receptors” PMID 36354040 ↗ Oct 2022 |
| Modality | Protein / enzyme biologic | — CHEMBL5095485 ↗ |
| Route | Subcutaneous | “Administered subcutaneously (SC)” NCT03841630 ↗ |
| Target | GCGR | “Glucagon receptor agonist” CHEMBL5095485 ↗ |
| Target | GIPR | “Gastric inhibitory polypeptide receptor agonist” CHEMBL5095485 ↗ |
| Target | GLP1R | “Glucagon-like peptide 1 receptor agonist” CHEMBL5095485 ↗ |